Cilofexor tromethamine
Based on 10 publication(s) in Google Scholar
Cilofexor tromethamine (GS-9674 tromethamine) is a nonsteroidal farnesene oxide receptor agonist with activity in improving markers of cholestasis and liver injury. Cilofexor tromethamine was shown to be well tolerated in patients without cirrhosis and resulted in significant improvements in liver biochemical parameters and cholestatic markers. Cilofexor tromethamine offers a potential inhibitory option for the management of primary sclerosing cholangitis.
For research use only. We do not sell to patients.
- CAS No.: 2253764-93-9
- Formula: C32H33Cl3N4O8
- Molecular Weight:707.99
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Cilofexor tromethamine
More- Science. 2023 Jun 9;380(6649):eabo2296. [Abstract]
- Nat Commun. 2024 May 13;15(1):4034. [Abstract]
- Arch Toxicol. 2022 Jun;96(6):1829-1843. [Abstract]
- JHEP Rep. 2023 Sep 25;6(1):100917. [Abstract]
- Biochem Biophys Res Commun. 2022 Mar 5:595:1-6. [Abstract]
- bioRxiv. 2024 June 11.
- Biomed Pharmacother. 2024 Apr:173:116331. [Abstract]
- bioRxiv. 2024 Feb 8:2023.11.20.567833. [Abstract]
- Université Laval. 2023 Nov 8.
- Patent. US20230310630A1.
-
RT-PCR
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
Biological Activity
Chemical Information
-
CAS No. 2253764-93-9
-
Molecular Weight 707.99
-
Formula C32H33Cl3N4O8
-
SMILES
O=C(C1=CC(N2CC(C3=CC=C(C=C3Cl)OCC4=C(C5CC5)ON=C4C6=C(Cl)C=CC=C6Cl)(C2)O)=NC=C1)O.OCC(CO)(CO)N
-
Synonyms
GS-9674 tromethamine
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Science
A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers. [Abstract]2023 Jun 9;380(6649):eabo2296. PMID: 37289890 -
Nat Commun
Mapping of mitogen and metabolic sensitivity in organoids defines requirements for human hepatocyte growth. [Abstract]2024 May 13;15(1):4034. PMID: 38740814 -
Arch Toxicol
Farnesoid X receptor (FXR) agonists induce hepatocellular apoptosis and impair hepatic functions via FXR/SHP pathway. [Abstract]2022 Jun;96(6):1829-1843. PMID: 35267068 -
JHEP Rep
Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice. [Abstract]2023 Sep 25;6(1):100917. PMID: 38074508
Cilofexor tromethamine purchased from MedChemExpress. Usage Cited in: JHEP Rep. 2023 Sep 25;6(1):100917. [Abstract]
Compared with the placebo group, spleen weight was reduced in the cilofexor (30 mg/kg), OCA + ASBTi, and cilofexor + ASBTi treatment groups, indicating a reduction in the inflammatory response in these groups.
Cilofexor tromethamine purchased from MedChemExpress. Usage Cited in: JHEP Rep. 2023 Sep 25;6(1):100917. [Abstract]
Cilofexor (30 mg/kg). Liver tissues were stained with hematoxylin-eosin (H&E), Sirius Red, CK7, PDGFRβ, α-SMA, COL1A1, and desmin.
-
Biochem Biophys Res Commun
Structural insight into the molecular mechanism of cilofexor binding to the farnesoid X receptor. [Abstract]2022 Mar 5:595:1-6. PMID: 35091108 -
-
Biomed Pharmacother
Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist. [Abstract]2024 Apr:173:116331. PMID: 38428307 -
bioRxiv
Hammerhead-type FXR agonists induce an eRNA FincoR that ameliorates nonalcoholic steatohepatitis in mice. [Abstract]2024 Feb 8:2023.11.20.567833. PMID: 38045226
Cilofexor tromethamine purchased from MedChemExpress. Usage Cited in: bioRxiv. 2024 Feb 8:2023.11.20.567833. [Abstract]
qPCR data showing FincoR expression levels in C57BL/6 mice liver respectively treated with GW4064 (30 mg/kg), Cilofexor (30 mg/kg), Tropifexor (0.5 mg/kg), Fexaramine (100 mg/kg), or OCA (20 mg/kg) for 1 h (n=3~4/group).
-
-
Purity & Documentation
References
[1]. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis [Content Brief]
[2]. Trauner M, et al. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801. [Content Brief]
[3]. Patel K, et al. Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial. Hepatology. 2020 Mar 1. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)